Evidence map›Paper›PMID 35373443›Full record

Trial reportBJU international2022

Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study).

Janet Athene Lane, Jenny L Donovan, Grace J Young, Michael Davis, Eleanor I Walsh, Kerry N L Avery, Jane M Blazeby, Malcolm D Mason, Richard M Martin, Tim J Peters and 20 more

Erratum issuedOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BJU international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 44 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 2 pooled it
11.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 83 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Relationship Values and Committed Actions Among Couples Coping with Prostate Cancer: A Qualitative Study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  7. MR Imaging/Ultrasound Fusion-Guided Biopsy and Primary Focal Therapy for Localized Prostate Cancer.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Prostate cancer screening.Asian journal of urology · 2025
    Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors at 14 institutions in 1 country.

Janet Athene LaneBristol Medical School, University of Bristol, Bristol, UK.ORCID 0000-0002-7578-4925
Jenny L DonovanBristol Medical School, University of Bristol, Bristol, UK.
Grace J YoungBristol Medical School, University of Bristol, Bristol, UK.
Michael DavisBristol Medical School, University of Bristol, Bristol, UK.
Eleanor I WalshBristol Medical School, University of Bristol, Bristol, UK.
Kerry N L AveryBristol Medical School, University of Bristol, Bristol, UK.
Jane M BlazebyBristol Medical School, University of Bristol, Bristol, UK.
Malcolm D MasonSchool of Medicine, Cardiff University, Cardiff, UK.
Richard M MartinBristol Medical School, University of Bristol, Bristol, UK.ORCID 0000-0002-7992-7719
Tim J PetersBristol Medical School, University of Bristol, Bristol, UK.
Emma L TurnerBristol Medical School, University of Bristol, Bristol, UK.
Julia WadeBristol Medical School, University of Bristol, Bristol, UK.
Prasad BollinaDepartment of Urology and Surgery, Western General Hospital, University of Edinburgh, Edinburgh, UK.
James W F CattoAcademic Urology Unit, University of Sheffield, Sheffield, UK.
Alan DohertyDepartment of Urology, Queen Elizabeth Hospital, Birmingham, UK.
David GillattDepartment of Urology, Southmead Hospital and Bristol Urological Institute, Bristol, UK.
Vincent GnanapragasamDepartment of Urology, Addenbrooke's Hospital, Cambridge, UK.ORCID 0000-0003-4722-4207
Owen HughesDepartment of Urology, Cardiff and Vale University Health Board, Cardiff, UK.
Roger KockelberghDepartment of Urology, University Hospitals of Leicester, Leicester, UK.
Howard KynastonDepartment of Urology, Cardiff and Vale University Health Board, Cardiff, UK.
Jon OxleyDepartment of Cellular Pathology, North Bristol NHS Trust, Bristol, UK.ORCID 0000-0002-4348-0273
Alan PaulDepartment of Urology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Edgar PaezDepartment of Urology, Freeman Hospital, Newcastle upon Tyne, UK.
Derek J RosarioAcademic Urology Unit, University of Sheffield, Sheffield, UK.
Edward RoweDepartment of Urology, Southmead Hospital and Bristol Urological Institute, Bristol, UK.
John StaffurthDivision of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK.
David E NealNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Freddie C HamdyNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
Chris MetcalfeBristol Medical School, University of Bristol, Bristol, UK.
Prostate Testing for Cancer and Treatment (ProtecT) Study Group
University of Bristol · GBAt Bristol · GBCardiff and Vale University Health Board · GBCardiff University · GBSouthmead Hospital · GBUniversity of Oxford · GBUniversity of Sheffield · GBAddenbrooke's Hospital · GBFreeman Hospital · GBLeeds Teaching Hospitals NHS Trust · GBNorth Bristol NHS Trust · GBQueen Elizabeth Hospital Birmingham · GBUniversity Hospitals of Leicester NHS Trust · GBWestern General Hospital · GB

Funding

Medical Research Council MR/K025643/1
6 · The paper itself

Abstract

objectiveTo investigate the functional and quality of life (QoL) outcomes of treatments for localised prostate cancer and inform treatment decision-making. PATIENTS AND

methodsMen aged 50-69 years diagnosed with localised prostate cancer by prostate-specific antigen testing and biopsies at nine UK centres in the Prostate Testing for Cancer and Treatment (ProtecT) trial were randomised to, or chose one of, three treatments. Of 2565 participants, 1135 men received active monitoring (AM), 750 a radical prostatectomy (RP), 603 external-beam radiotherapy (EBRT) with concurrent androgen-deprivation therapy (ADT) and 77 low-dose-rate brachytherapy (BT, not a randomised treatment). Patient-reported outcome measures (PROMs) completed annually for 6 years were analysed by initial treatment and censored for subsequent treatments. Mixed effects models were adjusted for baseline characteristics using propensity scores.

resultsTreatment-received analyses revealed different impacts of treatments over 6 years. Men remaining on AM experienced gradual declines in sexual and urinary function with age (e.g., increases in erectile dysfunction from 35% of men at baseline to 53% at 6 years and nocturia similarly from 20% to 38%). Radical treatment impacts were immediate and continued over 6 years. After RP, 95% of men reported erectile dysfunction persisting for 85% at 6 years, and after EBRT this was reported by 69% and 74%, respectively (P < 0.001 compared with AM). After RP, 36% of men reported urinary leakage requiring at least 1 pad/day, persisting for 20% at 6 years, compared with no change in men receiving EBRT or AM (P < 0.001). Worse bowel function and bother (e.g., bloody stools 6% at 6 years and faecal incontinence 10%) was experienced by men after EBRT than after RP or AM (P < 0.001) with lesser effects after BT. No treatment affected mental or physical QoL.

conclusionTreatment decision-making for localised prostate cancer can be informed by these 6-year functional and QoL outcomes.

Indexed as

BrachytherapyErectile DysfunctionProstatic NeoplasmsAgedAndrogen AntagonistsHumansMaleMiddle AgedProstateProstatectomyQuality of LifeTreatment OutcomeAndrogen Antagonistsfunctional outcomeslocalised prostate cancerpatient-reported outcomes#PCSM#ProstateCancerquality of lifetreatments#uroonc

Identifiers

PMID35373443
PMCPMC9543725
OpenAlexW4225815773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.